Bioaffinity Technologies, Inc.7月16日成交额为76.16万美元

市场透视2025-07-17

美东时间2025年7月16日，Bioaffinity Technologies, Inc.（BIAF.US）成交额为76.16万美元，成交额较昨日减少84.64%，当日成交量为237.82万股。Bioaffinity Technologies, Inc.（BIAF.US）于2025年7月16日涨12.97%，报0.331美元，该股过去5个交易日跌2.68%，年初至今跌63.64%，过去60日跌...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2552171950?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-17 09:21","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2552171950","market":"us","top_or_hot":-1,"title":"Bioaffinity Technologies, Inc.7月16日成交额为76.16万美元","media":"市场透视","content":"<div>\n<p>美东时间2025年7月16日，Bioaffinity Technologies, Inc.（BIAF.US）成交额为76.16万美元，成交额较昨日减少84.64%，当日成交量为237.82万股。Bioaffinity Technologies, Inc.（BIAF.US）于2025年7月16日涨12.97%，报0.331美元，该股过去5个交易日跌2.68%，年初至今跌63.64%，过去60日跌...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717092130a6ae7bbb&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bioaffinity Technologies, Inc.7月16日成交额为76.16万美元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioaffinity Technologies, Inc.7月16日成交额为76.16万美元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-17 09:21 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717092130a6ae7bbb&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>美东时间2025年7月16日，Bioaffinity Technologies, Inc.（BIAF.US）成交额为76.16万美元，成交额较昨日减少84.64%，当日成交量为237.82万股。Bioaffinity Technologies, Inc.（BIAF.US）于2025年7月16日涨12.97%，报0.331美元，该股过去5个交易日跌2.68%，年初至今跌63.64%，过去60日跌...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717092130a6ae7bbb&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BIAF","symbol_name":"bioAffinity Technologies, Inc.","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717092130a6ae7bbb&s=b","article_id":"2552171950","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717092130a6ae7bbb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2552171950","pubTimestamp":1752715281,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"美东时间2025年7月16日，Bioaffinity Technologies, Inc.成交额为76.16万美元，成交额较昨日减少84.64%，当日成交量为237.82万股。Bioaffinity Technologies, Inc.于2025年7月16日涨12.97%，报0.331美元，该股过去5个交易日跌2.68%，年初至今跌63.64%，过去60日跌35.75%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-07-16|76.16万|-84.64%|237.82万|#|2025-07-15|495.77万|1596.42%|1678.34万|#|2025-07-14|29.22万|78.86%|100.88万|#|2025-07-11|16.34万|-33.87%|54.12万|#|2025-07-10|24.71万|-79.30%|77.23万|bioAffinity Technologies Inc 致力于解决早期癌症和肺部疾病无创诊断以及靶向癌症治疗的需求。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BIAF":"bioAffinity Technologies, Inc.","BK4139":"生物科技"},"translate_title":"Bioaffinity Technologies, Inc. turnover of $761.6 K on July 16","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIAF":0.9},"content_text":"美东时间2025年7月16日，Bioaffinity Technologies, Inc.（BIAF.US）成交额为76.16万美元，成交额较昨日减少84.64%，当日成交量为237.82万股。Bioaffinity Technologies, Inc.（BIAF.US）于2025年7月16日涨12.97%，报0.331美元，该股过去5个交易日跌2.68%，年初至今跌63.64%，过去60日跌35.75%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-07-16|76.16万|-84.64%|237.82万|#|2025-07-15|495.77万|1596.42%|1678.34万|#|2025-07-14|29.22万|78.86%|100.88万|#|2025-07-11|16.34万|-33.87%|54.12万|#|2025-07-10|24.71万|-79.30%|77.23万|bioAffinity Technologies Inc 致力于解决早期癌症和肺部疾病无创诊断以及靶向癌症治疗的需求。公司使用能够优先靶向癌细胞和指示疾病状态的细胞群体的技术开发专有的无创诊断测试和癌症治疗药物。公司的产品CyPath Lung是一种用于检测早期肺癌的无创测试。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2552171950","isCrawlerRequest":true}